Search - tctmd.com

Displaying 201 - 220 of 342

Sort: Relevancy | Date

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Yael L. Maxwell

May 02, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Daily News

No Excuses: Routine, High-Volume Exercise in Men Not Associated With Increased Mortality

Michael O'Riordan

February 01, 2019

News Daily News

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Shelley Wood

January 15, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

Advertisement

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

No Need for Niacin? Meta-analysis Argues the End Is Nigh

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Quality of CAD Care Varies by Type of Medicare Coverage

No Excuses: Routine, High-Volume Exercise in Men Not Associated With Increased Mortality

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Top News in Clinical Cardiology: 2018

Top News in Policy & Practice: 2018

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content